顺铂处理大鼠有机阴离子转运体 5(Oat5)尿排泄的时程:一种用于早期检测药物诱导肾毒性的新型尿生物标志物。
Time course of organic anion transporter 5 (Oat5) urinary excretion in rats treated with cisplatin: a novel urinary biomarker for early detection of drug-induced nephrotoxicity.
机构信息
Area Farmacología, Facultad de Ciencias Bioquímicas y Farmacéuticas, Universidad Nacional de Rosario, CONICET, Suipacha 531, 2000, Rosario, Argentina.
出版信息
Arch Toxicol. 2015 Aug;89(8):1359-69. doi: 10.1007/s00204-014-1345-0. Epub 2014 Aug 28.
Cisplatin is a widely used citostatic drug employed in the treatment of many solid tumors. Its principal side-effect is nephrotoxicity. The organic anion transporter 5 (Oat5) is exclusively expressed in the kidneys. The aim of this study was to evaluate the time course of Oat5 urinary excretion and changes in conventional biomarkers, such as creatinine and urea plasma levels (Urp and Crp), and protein and glucose urinary levels (Pu and Gluu), between others, and compared them to the onset and progression of histological changes after cisplatin treatment. Male Wistar rats were treated with cisplatin with 5 mg/kg b.w., i.p., and experiments were carried out after 2, 4, 7 and 14 days of treatment. Two days after cisplatin administration, only Oat5 urinary excretion was found markedly modified. On day 4, Urp, Crp, PU and GluU were increased. By the seventh day, a severe impairment in tubular architecture was observed, and from this point and thereon, Oat5 urinary excretion and PU showed a tendency to return to their basal values. Meanwhile, Urp, Crp and GluU tended to return to their basal values by the day 14 of treatment, when kidney morphology showed an important recovery. So Oat5 urinary abundance was elevated 2 days after cisplatin treatment, when no modifications of traditional markers of renal injury were still observed. Therefore, the results showed in this work, in addition to previous data obtained by our group, propose that Oat5 urinary excretion might potentially serve as a noninvasive early biomarker of cisplatin-induced nephrotoxicity.
顺铂是一种广泛应用于多种实体瘤治疗的细胞抑制剂药物。其主要副作用是肾毒性。有机阴离子转运蛋白 5(Oat5)仅在肾脏中表达。本研究旨在评估 Oat5 尿排泄的时间过程以及其他常规生物标志物(如血浆肌酐和尿素水平(Urp 和 Crp)以及尿蛋白和葡萄糖水平(Pu 和 Gluu))的变化,并将其与顺铂治疗后组织学变化的发生和进展进行比较。雄性 Wistar 大鼠用 5mg/kg bw 的顺铂腹腔注射治疗,在治疗后 2、4、7 和 14 天进行实验。顺铂给药后 2 天,仅发现 Oat5 尿排泄明显改变。第 4 天,Urp、Crp、Pu 和 GluU 增加。第 7 天,观察到肾小管结构严重受损,从这一点开始,Oat5 尿排泄和 Pu 呈回到基础值的趋势。同时,Urp、Crp 和 GluU 在治疗的第 14 天趋于回到基础值,此时肾脏形态显示出重要的恢复。因此,Oat5 尿排泄在顺铂治疗后 2 天升高,此时仍未观察到肾损伤传统标志物的改变。因此,除了我们小组之前获得的数据外,本工作的结果表明,Oat5 尿排泄可能潜在地作为顺铂诱导的肾毒性的非侵入性早期生物标志物。